‘Sticky’ Particles Promise More Precise Drug Delivery for Brain Cancer
A Yale research team has found that by tinkering with the surface properties of drug-loaded nanoparticles, they can potentially direct these particles to specific cells in the brain. By making nanoparticles bioadhesive, or “sticky,” the researchers have answered a long-standing question: Once you get the particles to the brain, how do you get them to interact with the cancer cells there? “Until now, research has focused on whether you can load the nanoparticles with drugs and whether we can get them into the brain at all, without thinking too much about what cells they go to,” said senior author W. Mark Saltzman, the Goizueta Foundation Professor of Chemical and Biomedical Engineering, professor of cellular and molecular physiology and member of the Yale Cancer Center. “This is the first exploration of the particles’ affinity for different cells.”
Click here to read more.
71st Annual Meeting of the Southern Neurosurgical Society
Feb. 26-29, 2020; Richmond, Va.
3rd Annual Mayo Clinic Advances and Innovations in Complex Neuroscience Patient Care: Brain and Spine 2020
Feb. 27-29, 2020; Sedona, Ariz.
Multidisciplinary Neuro-Oncology Symposium: Updates in Medical and Surgical Management of Brain Tumors
March 6-7, 2020; Orlando, Fla.
5th Annual Safety in Spine Surgery Summit
March 12-13, 2020; New York
EANS Research Course & Young Neurosurgeons Meeting
March 26-28, 2020; Zurich